Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IKT
DateTimeSourceHeadlineSymbolCompany
18/06/202422:27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202413:05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
10/06/202421:20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
10/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
05/06/202413:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/06/202421:11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IKTInhibikase Therapeutics Inc
22/05/202413:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
20/05/202413:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
20/05/202413:01GlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
20/05/202412:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
16/05/202401:00GlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
15/05/202413:45GlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202412:56Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
09/05/202419:41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
18/04/202421:30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
03/04/202413:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
27/03/202420:15GlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/03/202413:30GlobeNewswire Inc.Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersNASDAQ:IKTInhibikase Therapeutics Inc
28/02/202421:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202412:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202412:55GlobeNewswire Inc.Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersNASDAQ:IKTInhibikase Therapeutics Inc
01/02/202421:49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
01/02/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
29/01/202414:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
16/01/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
16/01/202421:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliNASDAQ:IKTInhibikase Therapeutics Inc
19/12/202313:30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/12/202313:35GlobeNewswire Inc.Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT

Your Recent History

Delayed Upgrade Clock